Cost-Utility Analysis of Geriatric Assessment and Management in Older Adults With Cancer: Economic Evaluation Within 5C Trial
Authors:
- Yeva SahakyanYSYeva Sahakyan
- Qixuan LiQLQixuan Li
- Shabbir M.H. AlibhaiSAShabbir M.H. Alibhai
- Martine PutsMartine Puts
- Shant T. YeretzianSYShant T. Yeretzian
- Mohammed R. AnwarMAMohammed R. Anwar
- Sarah BrennenstuhlSBSarah Brennenstuhl
- Bianca McLeanBMBianca McLean
- Fay StrohscheinFSFay Strohschein
- George TomlinsonGTGeorge Tomlinson
- Aria WillsAWAria Wills
- Lusine AbrahamyanLALusine Abrahamyan
Open Access
- 1 January 2024
- journal article
- research article
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 42 (1) , 59-69
Abstract
PURPOSE: Geriatric assessment (GA) is a guideline-recommended approach to optimize cancer management in older adults. We conducted a cost-utility analysis alongside the 5C randomized controlled trial to compare GA and management (GAM) plus usual care (UC) against UC alone in older adults with cancer. METHODS: The economic evaluation, conducted from societal and health care payer perspectives, used a 12-month time horizon. The Canadian 5C study randomly assigned patients to receive GAM or UC. Quality-adjusted life-years (QALYs) were measured using the EuroQol five dimension-5L questionnaire and health care utilization using cost diaries and chart reviews. We evaluated the incremental net monetary benefit (INMB) for the full sample and preselected subgroups. RESULTS: A total of 350 patients were included, of whom 173 received GAM and 177 UC. At 12 months, the average QALYs per patient were 0.728 and 0.751 for GAM and UC, respectively (ΔQALY, −0.023 [95% CI, −0.076 to 0.028]). Considering a societal perspective, the total average costs (in 2021 Canadian dollars) per patient were $46,739 and $45,177 for GAM and UC, respectively (ΔCost, $1,563 [95% CI, −$6,583 to $10,403]). At a cost-effectiveness threshold of $50,000/QALY, GAM was not cost-effective compared with UC (INMB, −$2,713 [95% CI, −$11,767 to $5,801]). The INMB was positive ($2,984 [95% CI, −$7,050 to $14,179]; probability of being cost-effective, 72%) for patients treated with curative intent, but remained negative for patients treated with palliative intent (INMB, −$9,909 [95% CI, −$24,436 to $4,153]). Findings were similar considering a health care payer perspective. CONCLUSION: To our knowledge, this is the first cost-utility analysis of GAM in cancer. GAM was cost-effective for patients with cancer treated with curative but not with palliative intent. The study provides further considerations for future adoption of GAM in practice.Keywords
This publication has 30 references indexed in Scilit:
- Economic evaluations of comprehensive geriatric assessment in surgical patients: a systematic reviewJournal of Surgical Research, 2017
- Phase-specific and lifetime costs of cancer care in Ontario, CanadaBMC Cancer, 2016
- A Time Trade-off-derived Value Set of the EQ-5D-5L for CanadaMedical Care, 2016
- Cost-Effectiveness Analysis Alongside Clinical Trials II—An ISPOR Good Research Practices Task Force ReportValue in Health, 2015
- A Guide to Handling Missing Data in Cost-Effectiveness Analysis Conducted Within Randomised Controlled TrialsPharmacoEconomics, 2014
- Screening older cancer patients: first evaluation of the G-8 geriatric screening toolAnnals of Oncology, 2012
- Development and preliminary testing of the new five-level version of EQ-5D (EQ-5D-5L)Quality of Life Research, 2011
- Transferability of Economic Evaluations Across Jurisdictions: ISPOR Good Research Practices Task Force ReportValue in Health, 2009
- Use of comprehensive geriatric assessment in older cancer patients:Critical Reviews in Oncology/Hematology, 2005
- Missing Data, Imputation, and the BootstrapJournal of the American Statistical Association, 1994